WB, IP, ChIP
H M
Endogenous
55
Mouse IgG2a
#Q96RI1
9971
Product Information
Product Usage Information
For optimal ChIP results, use 10 μl of antibody and 10 μg of chromatin (approximately 4 × 106 cells) per IP. This antibody has been validated using SimpleChIP® Enzymatic Chromatin IP Kits.
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:200 |
| Chromatin IP | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human FXR/NR1H4 protein.
Background
The farnesoid X receptor (FXR/NR1H4) is a member of the nuclear hormone receptor superfamily and is a master regulator of bile acid synthesis. FXR/NR1H4 heterodimerizes with RXR-alpha upon activation by bile acids, which begins a regulatory cascade involving SHP and LRH-1 to control lipid homeostasis (1-5). FXR/NR1H4 has also been shown to be a critical regulator of glucose homeostasis (6,7). In addition to directly regulating genes, FXR/NR1H4 also plays a post transcriptional role in bile acid metabolism by transcribing the RNA-binding protein ZFP36L1, which in turn downregulates the key enzyme Cyp7a1 (8). Mutations in human FXR/NR1H4 have been shown to cause cholestasis and liver disease in neonatal patients (9). FXR/NR1H4 can also control Lgr5+ intestinal stem cell proliferation and its upregulation has been shown to inhibit colorectal cancer progression (10-12). Agonists against FXR/NR1H4 are being evaluated for various liver diseases and diabetes (13-16).
- Parks, D.J. et al. (1999) Science 284, 1365-8.
- Wang, H. et al. (1999) Mol Cell 3, 543-53.
- Laffitte, B.A. et al. (2000) J Biol Chem 275, 10638-47.
- Edwards, P.A. et al. (2002) J Lipid Res 43, 2-12.
- Goodwin, B. et al. (2000) Mol Cell 6, 517-26.
- Ma, K. et al. (2006) J Clin Invest 116, 1102-9.
- Zhang, Y. et al. (2006) Proc Natl Acad Sci U S A 103, 1006-11.
- Tarling, E.J. et al. (2017) J Clin Invest 127, 3741-54.
- Gomez-Ospina, N. et al. (2016) Nat Commun 7, 10713.
- Modica, S. et al. (2008) Cancer Res 68, 9589-94.
- Fu, T. et al. (2019) Cell 176, 1098-1112.e18.
- Qiao, P. et al. (2018) Oncol Rep 40, 2067-78.
- Pellicciari, R. et al. (2002) J Med Chem 45, 3569-72.
- Hirschfield, G.M. et al. (2015) Gastroenterology 148, 751-61.e8.
- Neuschwander-Tetri, B.A. et al. (2015) Lancet 385, 956-65.
- Genin, M.J. et al. (2015) J Med Chem 58, 9768-72.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation ChIP: Chromatin IP
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专